Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
基本信息
- 批准号:10166908
- 负责人:
- 金额:$ 62.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-15 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AchievementAcuteAddressBiologicalBiologyBlood VesselsBlood specimenCalcium Channel BlockersCessation of lifeClinicalCyclic AMPDNADataDiagnosisDiseaseEnrollmentFDA approvedFutureGenesGeneticGenetic DeterminismGenetic TranscriptionGenetic VariationGenomicsGenotypeGoalsGrantHeart failureIndividualLinkLungMeasuresMediatingMediator of activation proteinMedical RecordsMethodologyMolecularOntologyOutcomePathway interactionsPatient CarePatientsPatternPharmaceutical PreparationsPhenotypePrevalenceProductionProstaglandins IProteomicsPublishingPulmonary artery structureRNAReceptor ActivationReceptor GeneReportingSamplingSelection for TreatmentsSeverity of illnessSignal TransductionSingle Nucleotide PolymorphismTechniquesTestingVariantVasodilator Agentsbasebiobankclinical predictorscohortdrug efficacydrug response predictioneffective therapyendothelial stem cellexome sequencingexperimental studygenetic predictorsgenetic variantgenomic signaturehemodynamicsimprovedimproved outcomeindividual patientinsightmetabolomicspatient responseperipheral bloodprecision medicinepressureprospectiveprospective testpulmonary arterial hypertensionreceptorreceptor expressionresponsetranscriptomics
项目摘要
SUMMARY
Pulmonary arterial hypertension is a relentless disease characterized by vascular obliteration, right
heart failure and death. Although there are ten FDA-approved therapies in three classes for PAH,
none is curative and approximately 40% of patients are dead within 5 years of diagnosis. There is no
established approach to identify patients who will respond to a specific therapy and many patients
worsen while waiting for an effective therapy. The goals of this proposal are to improve outcomes in
PAH using the concepts of precision medicine through an advanced genetics and “Omics” approach
incorporating transcriptomics, proteomics and metabolomics. Within cohorts of unselected PAH
patients, there are two subsets with striking responses to therapy. One is a small subset that has a
marked reduction in pulmonary artery pressure acutely in response to vasodilators and a dramatic
long-term clinical response to calcium channel blocker therapy. We have recently published
peripheral blood transcriptomic and genomic signatures of calcium channel blocker responsive
patients differentiating them from non-responsive patients. The second subset is patients that have
marked improvement with parenteral prostacyclin therapy. We and others have reported
normalization of pulmonary arterial pressure in a subset of PAH patients treated with parenteral
prostacyclin therapy. In preliminary data, we have identified clinical predictors of long-term survival in
response to parenteral prostacyclin therapy and have found transcriptomic patterns that differentiate
these patients. We have also identified variability in expression of the prostacyclin receptor in
lymphoblastoids of control individuals and suppression of the receptor in PAH. We have preliminarily
identified genetic variants that regulate prostacyclin receptor expression and that differentiate patients
with good and poor responses to prostacyclin therapy. These data form the basis of our hypothesis
that peripheral blood-derived genetic and Omic profiles identify correlates of prostacyclin
responsiveness in PAH and can be exploited to understand mechanisms of drug efficacy and to
optimize patient care. In this grant we propose to 1) understand genetic variation contributing to
differential clinical response to prostacyclin therapy in PAH, 2) identify peripheral blood-derived Omic
profiles to identify patients with durable clinical responses to parenteral prostacyclin therapy, 3)
prospectively test our genetic and Omic profiles capacity to predict short-term responses to
prostacyclin therapy in PAH clinically treated with PPs. The long term goals of this proposal are to
better match a patient's unique biology to PP therapy, potentially improving survival in this highly
morbid disease.
摘要
肺动脉高压是一种以血管闭塞为特征的顽固性疾病,对吗?
心力衰竭和死亡。尽管FDA批准了三类10种治疗PAH的方法,
没有一种是治愈的,大约40%的患者在确诊后5年内死亡。没有
确定对特定治疗有反应的患者和许多患者的既定方法
在等待有效治疗的同时病情恶化。这项提案的目标是改善#年的成果
PAH通过先进的遗传学和OMICS方法使用精准医学的概念
融合了转录组学、蛋白质组学和代谢组学。在未选择的多环芳烃队列中
患者中,有两个亚组对治疗有显著反应。一种是一个子集,它有一个
对血管扩张剂的反应使肺动脉压显著降低
钙通道阻滞剂治疗的长期临床反应。我们最近发表了
钙通道阻滞剂反应性外周血转录和基因组特征
患者将他们与无反应的患者区分开来。第二个子组是那些有
前列环素肠外治疗效果显著。我们和其他人已经报道了
部分接受胃肠外治疗的PAH患者的肺动脉压正常化
前列环素治疗。在初步数据中,我们已经确定了长期存活的临床预测因素
对非肠道前列环素治疗的反应,并发现了不同的转录模式
这些病人。我们还鉴定了前列环素受体表达的变异性。
对照组的淋巴母细胞与PAH中受体的抑制。我们已经初步完成了
识别调节前列环素受体表达并区分患者的基因变异
对前列环素治疗有好有差的反应。这些数据构成了我们假设的基础
外周血源性遗传和基因组图谱确定了前列环素的相关性
多环芳烃的反应性,可被用来理解药物疗效的机制和
优化患者护理。在这笔赠款中,我们建议1)了解基因变异对
前列环素治疗PAH的不同临床反应:2)鉴定外周血源性基因组
确定对前列环素治疗有持久临床反应的患者的资料,3)
前瞻性地测试我们的基因和基因组图谱预测短期反应的能力
PPS治疗PAH的前列环素治疗这项提议的长期目标是
更好地将患者独特的生物学与PP疗法相匹配,潜在地提高了患者的存活率
病态的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna R Hemnes其他文献
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients
肺动脉高压未来治疗模式:来自医生、卫生当局和患者的个人观点
- DOI:
10.1016/s2213-2600(24)00425-9 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:32.800
- 作者:
Franck F Rahaghi;Marc Humbert;Marius M Hoeper;R James White;Robert P Frantz;Paul M Hassoun;Anna R Hemnes;Steven M Kawut;Vallerie V McLaughlin;Gergely Meszaros;Peter G M Mol;Steven D Nathan;Mitchel A Psotka;Farbod N Rahaghi;Olivier Sitbon;Norman Stockbridge;Jason Weatherald;Faiez Zannad;Sandeep Sahay - 通讯作者:
Sandeep Sahay
Anna R Hemnes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anna R Hemnes', 18)}}的其他基金
Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
- 批准号:
9926307 - 财政年份:2019
- 资助金额:
$ 62.21万 - 项目类别:
Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
- 批准号:
10402363 - 财政年份:2019
- 资助金额:
$ 62.21万 - 项目类别:
Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
- 批准号:
10393072 - 财政年份:2019
- 资助金额:
$ 62.21万 - 项目类别:
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension
肺动脉高压右心室脂质沉积
- 批准号:
9197665 - 财政年份:2015
- 资助金额:
$ 62.21万 - 项目类别:
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension
肺动脉高压右心室脂质沉积
- 批准号:
9474720 - 财政年份:2015
- 资助金额:
$ 62.21万 - 项目类别:
A molecular phenotype of combined pulmonary hypertension
合并性肺动脉高压的分子表型
- 批准号:
8796005 - 财政年份:2014
- 资助金额:
$ 62.21万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 62.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 62.21万 - 项目类别:
Operating Grants